Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of oxymetazoline nasal spray on physical capacity in COPD
2020-005013-40Phase 4Active
- Sponsor
- Sørlandet sykehus
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of xylometazoline in chronic obstructive pulmonary disease (COPD), sponsored by Sørlandet sykehus. Primary endpoint: Walking distance before and after nasal decongestion. Started Jan 2021; status: active.
02
Drugs
xylometazoline
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-005013-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005013-40.